Ditchcarbon
  • Contact
  1. Organizations
  2. Adimmune Corporation
Public Profile
Pharmaceutical Preparation Manufacturing
TW
updated 18 days ago

Adimmune Corporation Sustainability Profile

Company website

Adimmune Corporation, a leading biopharmaceutical company based in Taiwan (TW), has been at the forefront of vaccine development since its establishment in 1965. With a strong focus on the research, production, and distribution of vaccines, Adimmune has made significant strides in enhancing public health both locally and internationally. The company is renowned for its innovative vaccine solutions, including those for influenza and other infectious diseases, which are distinguished by their high efficacy and safety profiles. Adimmune's commitment to quality and research excellence has positioned it as a key player in the global vaccine market. Over the years, Adimmune has achieved numerous milestones, solidifying its reputation as a trusted provider of vaccines. Its strategic operations extend beyond Taiwan, reaching various regions, thereby contributing to global health initiatives and responding to emerging health challenges.

DitchCarbon Score

How does Adimmune Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

21

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Adimmune Corporation's score of 21 is lower than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.

25%

Let us know if this data was useful to you

Adimmune Corporation's reported carbon emissions

In 2023, Adimmune Corporation, headquartered in Taiwan (TW), reported total carbon emissions of approximately 16,779,000 kg CO2e. This figure includes 4,556,000 kg CO2e from Scope 1 emissions and 12,223,000 kg CO2e from Scope 2 emissions. The company's emissions data reflects a slight decrease from 2022, when total emissions were about 16,395,000 kg CO2e, with Scope 1 and Scope 2 emissions of 4,572,000 kg CO2e and 11,823,000 kg CO2e, respectively. Adimmune has not disclosed any Scope 3 emissions data, nor have they set specific reduction targets or initiatives as part of their climate commitments. The absence of documented reduction targets suggests that the company may be in the early stages of formalising its climate strategy. Overall, Adimmune Corporation's emissions profile indicates a commitment to monitoring and reporting its carbon footprint, although further steps may be necessary to establish clear reduction goals and initiatives in line with industry standards.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

202020212022
Scope 1
3,215,000
0,000,000
0,000,000
Scope 2
9,265,000
00,000,000
00,000,000
Scope 3
-
-
-

How Carbon Intensive is Adimmune Corporation's Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Adimmune Corporation's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Adimmune Corporation's Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Adimmune Corporation is in TW, which we do not have grid emissions data for.

Adimmune Corporation's Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Adimmune Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Adimmune Corporation's Emissions with Industry Peers

Regeneron

US
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Moderna

US
•
Pharmaceutical Preparation Manufacturing
Updated 10 days ago

Serum Institute of India Pvt. Ltd.

IN
•
Pharmaceutical Preparation Manufacturing
Updated 29 days ago

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated 10 days ago

Valneva

FR
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Novartis

CH
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy